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Abstract.
Background: Age and short leukocyte telomeres have been associated with a higher risk of Alzheimer’s disease (AD).
Inflammation is involved in AD and it is suggested that anti-inflammatory interleukin-10 (IL-10) may partly antagonize these
processes.
Objective: The aim is to correlate telomere length (TL) in peripheral blood mononuclear cells (PBMC) from patients with
AD to disease progression rate. Moreover, we evaluated whether TL was associated with IL-10 production by unstimulated or
amyloid- (A)-stimulated PBMC.
Methods: We enrolled 31 late-onset AD and 20 age-matched healthy elderly (HE). After a two-year follow-up period, patients
were retrospectively evaluated as slow-progressing (ADS) (Mini Mental State Examination (MMSE) decline over the two years
of follow-up ≤3 points) or fast progressing AD (ADF) (MMSE decline ≥5 points). TL was measured by flow cytometry and in
vitro IL-10 production by enzyme-linked immunosorbent assay.
Results: TL (mean ± SD) for HE, ADS, and ADF was 2.3 ± 0.1, 2.0 ± 0.1, and 2.5 ± 0.1 Kb, respectively. ADS showed a shorter
TL compared to HE (p = 0.034) and to ADF (p = 0.005). MMSE decline correlated with TL in AD (R2 = 0.284; p = 0.008). We
found a significant difference in IL-10 production between unstimulated and A-stimulated PBMC from ADS (40.7 ± 13.7
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versus 59.0 ± 27.0; p = 0.004) but not from ADF (39.7 ± 14.4 versus 42.2 ± 22.4). HE showed a trend toward significance
(47.1 ± 25.4 versus 55.3 ± 27.9; p = 0.10).
Conclusion: PBMC from ADF may be characterized by an impaired response induced by A and by a reduced proliferative
response responsible for the longer telomeres. TL might be a contributing factor in predicting the rate of AD progression.
Keywords: Alzheimer’s disease, disease progression, interleukin-10, peripheral blood mononuclear cells, telomere
INTRODUCTION
Alzheimer’s disease (AD) is the major cause of
dementia in the elderly. It is commonly accepted that
AD pathology starts years to decades before the onset
of cognitive symptoms [1]. This fact explains why
symptomatic AD consistently represents an advanced
stage of AD pathology [2].
Amyloid plaques and neurofibrillary tangles are the
pathological hallmarks of AD. However considering
AD as a single, well-defined entity has become an
obstacle to lucid analysis of the problem of dementia
in old age. Whereas in early-onset patients, AD might
be best described as a purely degenerative disease with
an important role for amyloid- (A) in the pathogen-
esis; in late-onset patients, the probability of finding
other abnormalities is increased [3–7]. To date, 90%
of all patients with AD in the population are older than
75 years, and 75% of patients are over 80 years of age
[8]. This data suggest that aging and pathophysiologi-
cal changes it induces may be joint causes of AD onset
and progression in older patients.
Telomeres are specialized sequences consisting of
highly conserved TTAGGG repeats [9–11] that cap
the ends of linear chromosomal DNA, protecting the
genome from damage and preserving chromosome
stability [10, 12–14]. However, because of their end
positions, telomeres are not fully duplicated during
DNA replication and thus become shorter with each
cell division [15–17]. This process limits the replica-
tive lifespan of many different cells that, eventually,
enter a senescent status or trigger apoptosis [18–23].
Telomere length (TL) reflects not only cellular turnover
but also the exposure to oxidative and inflammatory
damage [24–29] and, accordingly, may be a marker of
both biological age and mortality risk [27, 30–32] that
predicts incidence of age-related diseases [33–37]. To
date, investigations on blood cells have been incon-
sistent in relationship between TL and AD [38–47]. In
particular, several studies reported that TL is associated
with cognitive decline in elders [48–51] and is shorter
in patients with AD [38–44], but other studies showed
TL is not associated with either levels of cognitive
performance or age-related cognitive change [52, 53]
and cannot be used in elderly as marker to diagnose
the early phase of cognitive impairment (mild cog-
nitive impairment), to distinguish between demented
and non-demented patients and/or the type of dementia
[45–47].
A growing body of literature shows that inflam-
mation is involved in the neurodegeneration process
[54–58] and can furthermore accelerate telomere short-
ening [26–29], which, in turn, may be linked with
the pathogenesis of AD [38–44, 59–61]. Interest-
ingly, it is suggested that anti-inflammatory cytokines,
like interleukin-10 (IL-10), may partly antagonize
these processes [62, 63]. In particular, IL-10 has
been suggested to play an important role in neu-
ronal homeostasis and may also be able to inhibit
A- or lipopolysaccharide (LPS)-induced generation
of proinflammatory cytokines [64].
To investigate the contribution of telomere short-
ening to the onset and progression rate of AD, we
measured TL in peripheral blood mononuclear cells
(PBMC) from late-onset patients with AD and age-
matched controls, and we correlated it with disease
progression rate. We also assessed whether TL was
associated with IL-10 production by resting and A-
or LPS-stimulated PBMC. Here we report that TL is
directly associated with the rate of cognitive decline
during the follow-up period and may thus be consid-
ered as a predictive marker of AD progression rate.
In addition, an impaired response to A stimulus may
contribute to cause a faster AD progression.
MATERIALS AND METHODS
Participants and setting
A total of 51 individuals were enrolled in the study:
20 healthy elderly (HE) (mean age 79.1 ± 8.4 years
old) and 31 patients with AD (mean age 80.6 ± 5.1
years old). Subjects diagnosed with AD fulfilled the
criteria of dementia and the criteria of AD defined
by NINCDS-ADRDA [65]. All individuals were Cau-
casians living in Milan or Paris and belonged to larger
populations of outpatients.
The criteria for the diagnosis of normal cognition
were: 1) no active neurological or psychiatric disorder;
2) no ongoing medical problems or related treatments
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interfering with cognitive function; 3) a normal neu-
rological exam; 4) no psychoactive medications, and
5) the ability to live and function independently in the
community.
Individuals affected by cancer, cardiovascular dis-
eases, autoimmune disorders, inflammatory diseases,
and active neurological or psychiatric disorders were
excludedfromthestudy.Wealsoexcludedsubjectswho
exhibitedsignsof inflammation(asstatedbyhemogram
and C-reactive protein level) at the time of blood draw.
All participants and their relatives gave informed
consent and the study protocol was approved by the
respective ethics committees.
At baseline, physical, neurological, and neuropsy-
chological examinations were performed for all
patients with AD together with clinical history, com-
puted tomography or magnetic resonance imaging
scan, and cognitive testing using Mini-Mental State
Examination (MMSE). Laboratory analyses included
apolipoprotein E (ApoE) genotype assessment and bio-
chemical tests.
After a two-year period of follow-up, patients with
AD were retrospectively evaluated and AD progres-
sion rate was calculated by using deltaMMSE score
(MMSE score at recruitment - MMSE score after the
two-year period of follow-up). Subsequently, patients
were divided into slow (ADS) and fast (ADF) declin-
ers according to their rate of decline, that is lower or
higher than the median rate of decline in the total pop-
ulation during the two-year period of follow-up (3.5
points) [66]. As the size of our study groups is quite
small, we employed more stringent classification cri-
teria and we defined patients showing a deltaMMSE
≤3 points and no appearance of new cognitive disor-
ders and/or physical deterioration as ADS and patients
showing a deltaMMSE ≥5 points and appearance of
new cognitive disorders as ADF. Noteworthy, all diag-
noses of slow or fast progressing AD were confirmed
by clinicians.
After the two-year period of follow-up, we repeated
for each HE the tests for the diagnosis of normal cogni-
tionandallof themfulfilled thecriteriaaforementioned.
After the follow-up period, participants were asked to
fast overnight and 20 ml of venous blood was drawn
from each subject between 7.30 and 9.00 a.m.
ApoE genotyping
Genomic DNA was extracted from whole blood by
using a salting-out method [67] and ApoE genotype
was determined as previously described [68].
PBMC isolation
PBMC were collected from whole blood by
using a density gradient centrifugation procedure
(Lympholyte-H kit Cedarlane Laboratories Limited,
Burlington, ON) and stored at −80◦C pending
analysis.
Flow cytometry
TL was determined by flow cytometry using the
telomere PNA kit/FITC® (Dako Italia, Milan, IT)
following manufacturer’s directions. This Kit allows
calculating relative telomere length (RTL) of sam-
ple cells (SC) using control cells (CC) with a known
TL. The tetraploid 1301 cell line (Biologic Bank
and Cell Factory, Genoa, IT) with a TL of approxi-
mately 25 Kb [69] was used as CC. The employed
PNA telomere probe binds solely the telomere repeat
sequences and does not bind to subtelomeric regions,
which appear to be in the range of 2–4 kb in length.
We prepared a 1:1 mixture of SC and CC, using
500,000 cells from each subject, and included 2 pos-
itive and 2 negative samples in each evaluation. In
all samples, DNA was denatured for 10 min at 82◦C
either in the presence of hybridization solution without
probe (negative) or in hybridization solution con-
taining fluorescein-conjugated PNA telomere probe
(positive). Hybridization was carried out overnight,
in the dark at room temperature. After two washes
at 40◦C, samples were stained with propidium iodide
(PI) for 4 h at 4◦C for the identification of cells in
G0/G1 phases and the DNA index calculation. Sam-
ples were then acquired with a FACSCanto II (Becton
Dickinson, Franklin Lakes, NJ) and analyzed with
a Kaluza® software (Beckman Coulter, Indianapo-
lis, IN). For each tube, a total of 30,000 cells were
analyzed. RTL was calculated with the following for-
mula with the correction for the DNA index of G0/1
cells:
RTL = (mean FL1 sample cells with probe–mean FL1 sample cells without probe) × DNA index of control cells × 100(mean FL1 control cells with probe–mean FL1 control cells without probe) × DNA index of sample cells
The absolute TL was calculated by multiplying RTL
for 25 Kb.
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Telomere length polymerase chain reaction
Genomic DNA was extracted from PBMC [68] and
stored at −80◦C pending analysis. To confirm flow
cytometry data, TL was reassessed by using a quan-
titative PCR (q-PCR) method as previously reported
[70]. Briefly, we determined the relative ratio (T/S
ratio) of telomere (T) repeat copy number to a single
copy gene (S) copy number using a comparative quan-
titation approach. The adopted primer pairs, their final
concentration and the thermal cycling profiles were
exactly as described [71] except that the number of
amplification cycles was increased to 30 and 40 for the
T and S reactions, respectively. In each well, an aliquot
of 10 ng (10l) template DNA was added containing
12l SYBR Select Master Mix (Applied Biosystem,
Foster City, CA) and 3l of primers. Before running
samples, the linear range of T and S assay was deter-
mined by generating a standard curve using a serially
diluted DNA (from 70 to 2.2 ng in 2-fold dilutions) in
triplicate. Both T and S reactions showed good linearity
across this input range (r² >0.99). A calibrator sample
(a mixture of several DNAs) and a negative control
were included on each plate. All q-PCR assays were
performed on an ABI 7500 system (Applied Biosys-
tem, Foster City, CA) and each sample, including the
calibrator, was run in triplicate. For each T and S
q-PCR assay, raw data were exported from the ABI sys-
tem and imported into the LinRegPCR program. Then,
the program automatically calculated the fluorescence
threshold for all samples, the individual threshold cycle
and the mean efficiency of the run [72]. Mean effi-
ciency was used in calculating the T and S relative
concentration of each sample relative to the calibrator
sample [72]. TL was expressed as T/S ratio. To con-
firm TL measurements, all samples were re-run and
the inter-assay coefficient of variation (CV) was <5%.
In vitro IL-10 production
PBMC were resuspended at 3 × 106 ml in com-
plete medium (RPMI, 10% FBS, 2% PS, 1% L-Glu)
and were either unstimulated or stimulated with LPS
(Sigma, St. Louis, MO) or with a pool of three pep-
tides from the A protein as follows: fragment 1–16
(1g/ml), fragment 25–35 (10g/ml), and fragment
1–40 (25g/ml) (Innovagen, Lund, Sw) at 37◦C, 5%
CO2 atmosphere. Supernatants were harvested after
48 h for LPS stimulation and after 5 days of culture
for the A protein peptides. Production of IL-10 by
PBMC was evaluated with commercial Ready-SET-
Go! ELISA kit (eBioscience, Paris, Fr). The sensitivity
(limit of detection) of the employed ELISA assay
was 2 pg/ml. All tests kits were used following man-
ufacturer’s directions and, for each sample, data on
both PBMC IL-10 production and proliferation activity
were also normalized based on the ratio of living/dead
cells.
Statistical analysis
Statistical analysis was performed by using SPSS
statistical package (SPSS version 20, Chicago, IL).
Gender and ApoE 4 allelic distribution across groups
were assessed by the χ2-test. Demographic data,
MMSE scores, and TL were examined by ANOVA
univariate, followed by Bonferroni post-hoc test. The
correlation between TLs measured by flow cytome-
try (kb) and TL measured by q-PCR (T/S ratio) and
between TL (kb) and deltaMMSE scores was per-
formed by linear regression analysis. Differences in
IL-10 production between groups were evaluated by
the Kruskal-Wallis test or by Mann-Whitney U-test
where appropriate. Differences within groups between
unstimulated and A stimulated IL-10 productions
were assessed by the Wilcoxon signed rank test. We
adopted p < 0.05 as the threshold value for the statisti-
cal significance.
RESULTS
Characteristic of study population
Table 1 displays the demographic and clinical char-
acteristics of participants. Despite the non-significant
result obtained for the ApoE 4 distribution
(p = 0.095), the groups show clear differences in the
numbers of 4 allele carriers (Table 1). No difference
in gender distribution (Table 1) and in the percentage
of patients treated with acetylcholinesterase inhibitors
was found between ADS and ADF (75% versus 55%,
respectively, p = 0.432). At recruitment, ADS and ADF
showed a similar mean MMSE score. Conversely,
after the two-year period of follow-up, ADF exhib-
ited a significantly lower score than ADS (p < 0.001).
Accordingly, deltaMMSE, indicating the rate of dis-
ease progression, was significantly higher in ADF
(p < 0.001) (Table 1).
Telomere length analysis
TL evaluated by the mean of flow cytometry
(mean ± S.D.) was first compared between total
patients with AD and HE and no difference was found
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Table 1
Demographic and clinical characteristics of healthy elderly individuals (HE), slow-progressing AD patients (ADS) and fast-progressing AD
patients (ADF)
HE (n = 20) ADS (n = 20) ADF (n = 11) p value
Age, mean ± S.D. 79.1 ± 8.4 80.8 ± 5.7 80.4 ± 4.1 0.919
Gender, female, % 50.0 60.0 81.8 0.104
ApoE 4, carriers, % 30.0 55.0 54.5 0.095
ApoE 4, homozygosity, % 0.0 5.0 0.0 0.454
MMSE at recruitment, mean ± S.D. 29.1 ± 1.4a,b 20.4 ± 4.7 19.9 ± 6.1 <0.001
MMSE after the follow-up period, mean ± S.D. 28.9 ± 1.5a,b 19.6 ± 4.6 12.3 ± 5.4a <0.001
deltaMMSE, mean ± S.D. 0.2 ± 0.1a,b 0.8 ± 1.4 7.9 ± 3.5a <0.001
TL (flow cytometry), kb, mean ± S.D. 2.3 ± 0.4a 2.0 ± 0.4 2.5 ± 0.4a 0.003
ap < 0.05 versus ADS; bp < 0.05 versus ADF.
Fig. 1. Telomere length (kb) comparison between (a) HE and total AD (b) HE, ADS, and ADF.
(2.1 ± 0.5 versus 2.3 ± 0.4 Kb, respectively, p = 0.135)
(Fig. 1a).
Subsequently, patients were categorized as fast or
slow progressing based on disease progression rate.
This further classification led to the finding that ADS
displayed shorter telomeres not only compared to HE
(2.0 ± 0.4 versus 2.3 ± 0.4 kb; p = 0.034) but also to
ADF (2.0 ± 0.4 versus 2.5 ± 0.4 kb; p = 0.005) (Table 1
and Fig. 1b).
Patients that are homozygous for ApoE 4 have been
reported to show significantly shorter TL than those
with only one ApoE 4 copy or other ApoE alleles [45].
In our study population there is only one individual
homozygous for ApoE 4 (Table 1), an ADS showing
a TL of 2.02 kb, which reflect the mean TL of ADS
group.
In order to confirm flow cytometry data, TL mea-
surements obtained by flow cytometry were compared
to TL measurements obtained by q-PCR, showing a
very strong correlation (R2 = 0.523; p < 0.001).
IL-10 production in resting and Aβ- or
LPS-stimulated PBMC
There was no difference in IL-10 production
between the study groups (Table 2). In contrast, when
unstimulated and A stimulated IL-10 productions
at day 5 were compared within groups, a significant
Table 2
IL-10 production from unstimulated PBMC and after stimulation with LPS or A
HE (n = 18) ADS (n = 20) ADF (n = 10) p value
Unstimulated IL-10 production (pg/ml) (day 2), median ± MAD 21.0 ± 6.0 23.2 ± 5.7 16.2 ± 4.9 0.629
Unstimulated IL-10 production (pg/ml) (day 5), median ± MAD 47.1 ± 25.4 40.7 ± 13.7 39.7 ± 14.4 0.820
LPS-stimulated IL-10 production (pg/ml) (day 2), median ± MAD 485 ± 249 671 ± 285 797 ± 223 0.928
A-stimulated IL-10 production (pg/ml) (day 5), median ± MAD 55.3 ± 27.9 59.0 ± 27.0 42.2 ± 22.4 0.286
Number of unstimulated living PBMC (millions/ml) (day 2), mean ± S.D. 1.54 ± 0.28 1.53 ± 0.24 1.43 ± 0.22 0.430
Number of unstimulated living PBMC (millions/ml) (day 5), mean ± S.D. 1.32 ± 0.13 1.31 ± 0.26 1.29 ± 0.23 0.932
Number of LPS-stimulated living PBMC (millions/ml) (day 2), mean ± S.D. 1.49 ± 0.12 1.41 ± 0.12 1.39 ± 0.12 0.342
Number of A-stimulated living PBMC (millions/ml) (day 5), mean ± S.D. 1.28 ± 0.12a 1.30 ± 0.26a 1.09 ± 0.29 0.050
MAD, median absolute deviation. ap < 0.05 versus ADF. Missing data from 2 HE and 1 ADF.
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Fig. 2. Correlation adjusted for age, gender and ApoE 4 genotype
between TL and deltaMMSE score in patients with AD (R2 = 0.284;
p = 0.008).
Fig. 3. IL-10 production comparison at day 5 between unstimulated
(open symbols) and A stimulated (solid symbols) PBMC.
positive difference was found in ADS (40.7 ± 13.7
versus 59.0 ± 27.0; p = 0.004) (Fig. 3). Likewise, HE
showed a trend close to significance (47.1 ± 25.4 ver-
sus 55.3 ± 27.9; p = 0.10). Interestingly, ADF did not
show such a difference, suggesting a lack of response to
A stimulus (39.7 ± 14.4 versus 42.2 ± 22.4; p = 0.94)
(Fig. 3).
Moreover, the concentration of A stimulated
PBMC at day 5 was significantly lower for ADF
compared to both ADS (1.09 ± 0.29 and 1.30 ± 0.27
million PBMC/ml respectively; p = 0.050) and HE
(1.09 ± 0.29 and 1.28 ± 0.12 million PBMC/ml
respectively; p = 0.024) (Table 2). Interestingly, we
found no significant difference in the concentration
of both unstimulated PBMC (after 2 and 5 days of
culture) and LPS-stimulated PBMC between the study
groups, suggesting that PBMC from ADF may have an
impaired A-induced but not physiologic proliferative
response.
TL directly correlates with deltaMMSE score
We found a direct correlation in total patients
with AD between TLs (kb) and deltaMMSE scores
(R2 = 0.284; p = 0.008) (Fig. 2). However, we found no
significant correlation between TLs and A-induced
IL-10 production either considering all the enrolled
individuals (p = 0.448) or considering only the patients
with AD (p = 0.530) (data not shown).
DISCUSSION
Even though telomere shortening has been associ-
ated with neurodegeneration, dementia risk and AD
etiopathogenesis, literature data have shown conflict-
ing results. Our study showed no difference in TL
between AD subjects compared to controls. Neverthe-
less, when patients were categorized based on disease
progression rate, a difference in TL was found. In line
with our results, a recent in vivo study showed that
telomere shortening is associated with a slower cog-
nitive decline in APP23 mice, a mouse model of AD
[73].
Inflammation is considered to be involved in AD
etiopathogenesis through effects on neuronal home-
ostasis and immune response [54–58]. In addition, the
immune system of AD subjects is reported to be poorly
responsive to A as it exhibits a reduced ability to
phagocytize amyloid peptides [74] and a severe lack of
proliferative responsiveness to amyloid stimulus [75].
Our previous case-control study showed a decreased
A-stimulated production of IL-10 in PBMC from
patients with AD [68], and the present data highlighted
in ADF a lack of IL-10 increase after A stimulus,
suggesting an antigen-specific impairment in the pro-
duction of this cytokine.
In addition, A-stimulated PBMC from ADF
showed a significantly lower proliferative response
when compared to A stimulated PBMC from both
ADS and HE, also suggesting an impaired proliferative
response to the stimulation induced by A in ADF. We
speculate that PBMC from ADF may be characterized
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by an impaired capacity to respond to the inflamma-
tory stimulus induced by A. This may lead not only
to a lower A induced IL-10 production but also to an
impaired A induced proliferative response. As telom-
eres get shorter and shorter every time a cell divides, a
reduced proliferative response to A may be respon-
sible for the maintained TL in ADF. On the contrary,
PBMC from ADS may be able to better respond to
A. Accordingly, an overstimulation of PBMC from
ADS may occurs during the progression of the pathol-
ogy, leading to both a higher proliferative and telomere
shortening rate compared to ADF and HE.
Our data and APP23 mice investigations [73]
showed shorter telomeres in those exhibiting a slower
rate of disease progression. However, considering
telomere shortening as a beneficial process with regard
to the rapidity of AD progression requires further
experimental and clinical evidences.
The strength of the present study is the further clas-
sification of AD patients in two sub-groups, which are
characterized by a different progression rate (and may
display different peculiar characteristics). Conversely,
its weakness is the small size of the study population.
This may be responsible for the lack of signifi-
cant differences in IL-10 productions between groups,
notwithstanding the disparity in terms of median val-
ues between ADS and ADF. The small sample size may
also be responsible for the absence of significant differ-
ences in APOE 4 distribution between patients with
AD and HE. Contributing factors to telomere short-
ening lie in lifestyle factors (e.g., physical activity,
overall quality of life, perceived stress, smoking, nico-
tine and alcohol consumption) and health status. We
did not compare the study groups for lifestyle factors
and prevalence of age-related diseases and this may be
another limitation of our study.
Our preliminary investigation confirms previ-
ous literature data suggesting PBMC as peripheral
biomarkers that may mirror alterations within the dis-
eased brain [76]. Moreover, we showed in ADF a
longer TL and a lack of IL-10 increase in response to
A stimulus. The significant direct correlation between
TLs and deltaMMSE scores indicates that TL may have
a role as predictive marker of AD progression rate.
The assessment of how rapidly AD is aggravating has
important implications in clinical practice, since the
rate of disease progression may be the most important
factor in determining prognosis [77, 78].
Other investigations, with larger study groups, are
necessary to clarify the mechanisms responsible for
the different course of the pathology in ADS and
ADF.
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